Subcutaneous Implantable Cardioverter-Defibrillators in Patients With Congenital Heart Disease. Victor Waldmann , Christelle Marquié , Francis Bessière , David Perrot , Frédéric Anselme , Nicolas Badenco , Sergio Barra , Géraldine Bertaux , Hugues Blangy , Pierre Bordachar , Serge Boveda , Michel Chauvin , Nicolas Clémenty , Gaël Clerici , Nicolas Combes , Pascal Defaye , Jean-Claude Deharo , Philippe Durand , Guillaume Duthoit , Romain Eschalier , Laurent Fauchier , Rodrigue Garcia , Olivier Geoffroy , Edouard Gitenay , Jean-Baptiste Gourraud , Charles Guenancia , Laurence Iserin , Peggy Jacon , Laurence Jesel-Morel , Fawzi Kerkouri , Didier Klug , Linda Koutbi , Fabien Labombarda , Magalie Ladouceur , Gabriel Laurent , Christophe Leclercq , Baptiste Maille , Alice Maltret , Grégoire Massoulié , Pierre Mondoly , Sandro Ninni , Pierre Ollitrault , Jean-Luc Pasquié , Bertrand Pierre , Pénélope Pujadas , Laure Champ-Rigot , Frédéric Sacher , Nicolas Sadoul , Alexandre Schatz , Pierre Winum , Paul-Ursmar Milliez , Vincent Probst , Eloi Marijon Journal of the American College of Cardiology（2023）
摘要
In this nationwide study, patients with CHD represented 2% of all S-ICD implantations. Our findings emphasize the effectiveness and safety of S-ICD in this particularly high-risk population. (S-ICD French Cohort Study [HONEST]; NCT05302115).
更多 查看译文
关键词
congenital heart disease, heart disease, cardioverter-defibrillators
AI 理解论文
溯源树
样例
